KR102117202B1 - 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법 - Google Patents

항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법 Download PDF

Info

Publication number
KR102117202B1
KR102117202B1 KR1020197022418A KR20197022418A KR102117202B1 KR 102117202 B1 KR102117202 B1 KR 102117202B1 KR 1020197022418 A KR1020197022418 A KR 1020197022418A KR 20197022418 A KR20197022418 A KR 20197022418A KR 102117202 B1 KR102117202 B1 KR 102117202B1
Authority
KR
South Korea
Prior art keywords
ser
leu
val
pro
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197022418A
Other languages
English (en)
Korean (ko)
Other versions
KR20190094478A (ko
Inventor
주타 아메르스도르페르
슈테판 슈테이들
마르크 빈테리히
수잔 크론
리사 로즈크예르
Original Assignee
모르포시스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게 filed Critical 모르포시스 아게
Publication of KR20190094478A publication Critical patent/KR20190094478A/ko
Application granted granted Critical
Publication of KR102117202B1 publication Critical patent/KR102117202B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020197022418A 2011-08-16 2012-08-14 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법 Active KR102117202B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161523862P 2011-08-16 2011-08-16
EP11177660 2011-08-16
EP11177660.5 2011-08-16
US61/523,862 2011-08-16
PCT/EP2012/065904 WO2013024095A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a purine analog

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147006942A Division KR20140071368A (ko) 2011-08-16 2012-08-14 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207014644A Division KR20200060779A (ko) 2011-08-16 2012-08-14 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법

Publications (2)

Publication Number Publication Date
KR20190094478A KR20190094478A (ko) 2019-08-13
KR102117202B1 true KR102117202B1 (ko) 2020-06-01

Family

ID=47714800

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197022418A Active KR102117202B1 (ko) 2011-08-16 2012-08-14 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
KR1020207014644A Withdrawn KR20200060779A (ko) 2011-08-16 2012-08-14 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
KR1020147006942A Ceased KR20140071368A (ko) 2011-08-16 2012-08-14 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020207014644A Withdrawn KR20200060779A (ko) 2011-08-16 2012-08-14 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
KR1020147006942A Ceased KR20140071368A (ko) 2011-08-16 2012-08-14 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법

Country Status (25)

Country Link
US (3) US20140227277A1 (enExample)
EP (2) EP2744826B1 (enExample)
JP (1) JP6114273B2 (enExample)
KR (3) KR102117202B1 (enExample)
CN (1) CN103703027B (enExample)
AU (1) AU2012296905B2 (enExample)
BR (1) BR112013033916B1 (enExample)
CA (1) CA2841738C (enExample)
CY (1) CY1125148T1 (enExample)
DK (1) DK2744826T3 (enExample)
ES (1) ES2909720T3 (enExample)
HR (1) HRP20220224T1 (enExample)
HU (1) HUE058855T2 (enExample)
IL (1) IL230295B (enExample)
LT (1) LT2744826T (enExample)
MX (1) MX353589B (enExample)
PL (1) PL2744826T3 (enExample)
PT (1) PT2744826T (enExample)
RS (1) RS63121B1 (enExample)
RU (1) RU2664462C9 (enExample)
SG (1) SG10201606788VA (enExample)
SI (1) SI2744826T1 (enExample)
SM (1) SMT202200160T1 (enExample)
WO (1) WO2013024095A1 (enExample)
ZA (1) ZA201401835B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2523901B1 (es) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica
IL249533A0 (en) * 2014-06-16 2017-02-28 Xencor Inc Treatment of chronic lymphocytic leukemia
EP3157553A4 (en) * 2014-06-16 2018-02-28 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
WO2016189014A1 (en) 2015-05-26 2016-12-01 Morphosys Ag Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
EP3954388A1 (en) 2015-08-21 2022-02-16 MorphoSys AG Combinations and uses thereof
HRP20210938T1 (hr) * 2016-05-30 2021-09-03 Morphosys Ag Postupci za prognozu terapijske dobrobiti od anti-cd19 terapije kod pacijenata
IL320372A (en) * 2016-10-28 2025-06-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and uses thereof
LT3630177T (lt) 2017-05-31 2023-10-25 Morphosys Ag Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu
US11634488B2 (en) 2017-07-10 2023-04-25 International—Drug—Development—Biotech Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
JP2025500411A (ja) * 2021-12-22 2025-01-09 インサイト・コーポレイション 抗ｃｄ１９抗体療法のための治療パラダイム
WO2025012080A1 (en) 2023-07-13 2025-01-16 Christian-Albrechts-Universität Zu Kiel Humanized anti-cd7 antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100272723A1 (en) * 2006-08-14 2010-10-28 Xencor, Inc. Optimized Antibodies that Target CD19
US20110165152A1 (en) * 2009-08-14 2011-07-07 Martin Dreyling Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11852A (en) 1854-10-31 Abraham bassford
US106A (en) 1915-08-24 Specipication
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
DE69939939D1 (de) * 1998-08-11 2009-01-02 Idec Pharma Corp Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
KR20020020730A (ko) 1999-06-09 2002-03-15 오트리브 데이비스 더블유 Ｂ-세포를 표적하는 항체를 이용한 자가면역질환의 면역치료
KR20040023565A (ko) 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
JP2005512044A (ja) 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
KR20080032097A (ko) 2005-06-20 2008-04-14 메다렉스, 인코포레이티드 씨디19 항체 및 그의 용도
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
DK2270050T3 (da) * 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
MX2009002414A (es) 2006-09-08 2009-05-20 Medimmune Llc Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
EP3392273A1 (en) * 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
AU2010314905A1 (en) * 2009-11-06 2012-05-24 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100272723A1 (en) * 2006-08-14 2010-10-28 Xencor, Inc. Optimized Antibodies that Target CD19
US20110165152A1 (en) * 2009-08-14 2011-07-07 Martin Dreyling Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone

Also Published As

Publication number Publication date
EP4083071A2 (en) 2022-11-02
SMT202200160T1 (it) 2022-05-12
CN103703027B (zh) 2018-01-12
US20240424012A1 (en) 2024-12-26
EP2744826B1 (en) 2022-02-09
KR20140071368A (ko) 2014-06-11
IL230295B (en) 2018-03-29
JP6114273B2 (ja) 2017-04-12
US20200352975A1 (en) 2020-11-12
CA2841738C (en) 2022-12-06
SI2744826T1 (sl) 2022-05-31
WO2013024095A1 (en) 2013-02-21
HUE058855T2 (hu) 2022-09-28
CY1125148T1 (el) 2024-12-13
KR20190094478A (ko) 2019-08-13
KR20200060779A (ko) 2020-06-01
DK2744826T3 (da) 2022-03-28
US20140227277A1 (en) 2014-08-14
CN103703027A (zh) 2014-04-02
JP2014525925A (ja) 2014-10-02
PL2744826T3 (pl) 2022-05-30
RU2664462C2 (ru) 2018-08-17
CA2841738A1 (en) 2013-02-21
RU2014103490A (ru) 2015-09-27
AU2012296905B2 (en) 2017-01-05
EP2744826A1 (en) 2014-06-25
BR112013033916A2 (pt) 2017-11-28
NZ617771A (en) 2016-01-29
HRP20220224T1 (hr) 2022-04-29
LT2744826T (lt) 2022-04-25
MX353589B (es) 2018-01-19
RS63121B1 (sr) 2022-05-31
BR112013033916B1 (pt) 2022-11-16
ZA201401835B (en) 2015-06-24
RU2664462C9 (ru) 2018-09-28
EP4083071A3 (en) 2023-02-22
PT2744826T (pt) 2022-05-19
MX2013014935A (es) 2014-07-09
SG10201606788VA (en) 2016-09-29
ES2909720T3 (es) 2022-05-10

Similar Documents

Publication Publication Date Title
KR102117202B1 (ko) 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
US20240009196A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
AU2022202800B2 (en) Combinations and uses thereof
KR102115203B1 (ko) 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
AU2012296905A1 (en) Combination therapy with an anti - CD19 antibody and a purine analog
JP2014525925A5 (enExample)
HK1251152A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
HK1195322A (en) Combination therapy with an anti-cd19 antibody and a purine analog
HK1195322B (en) Combination therapy with an anti-cd19 antibody and a purine analog
NZ617771B2 (en) Combination therapy with an anti - cd19 antibody and a purine analog

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190730

Application number text: 1020147006942

Filing date: 20140314

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190917

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200224

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200525

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200525

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240520

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20250521

Start annual number: 6

End annual number: 6